Eugia Pharma Receives USFDA Approval for Leuprolide Acetate Injection 14 mg/2.8 mL MDV (Kit)

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Leuprolide Acetate Injection 14 mg/2.8 mL MDV.

Each 14-day kit contains:

• One Leuprolide Acetate Injection
• 14 mg/2.8 mL multiple-dose vial
• Patient Instructions for Use14 disposable syringes
• 28 alcohol swab

Indications for this product include:

• Palliative treatment of advanced prostatic cancer.

Refer to package insert for full prescribing information.